ADVENTRX Presents Positive Thiovir Preclinical Results
April 03 2006 - 5:00AM
PR Newswire (US)
SAN DIEGO, April 3 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that data were
presented showing strong antiviral synergy without added
cytotoxicity with combinations of Thiovir(TM) and zidovudine (AZT)
in a series of in vitro tests serving as models for human
immunodeficiency virus (HIV) infection. The data were presented on
Friday, March 31 at the HIV Pathogenesis Meeting, in Keystone,
Colorado. The abstract entitled "Synergistic antiviral activity and
additive cytotoxicity of Thiovir combined with zidovudine" was
presented by Shani Waninger, Ph.D., associate director of research
and development for ADVENTRX. Thiovir is a broad spectrum antiviral
and oral prodrug for foscarnet, a drug approved to treat
opportunistic infections in HIV/AIDS patients. Thiovir is being
developed as a reverse transcriptase inhibitor to be used as a
component of highly active antiretroviral therapy (HAART) for
HIV/AIDS and as a potential antiviral therapy for avian flu.
Results were presented from in vitro tests that revealed various
combinations of Thiovir and zidovudine showed strong synergistic
antiviral activity. This antiviral synergy between Thiovir and
zidovudine was significantly more pronounced than antiviral
activity of combinations of foscarnet and zidovudine, which were
found to be only slightly synergistic to antagonistic. Furthermore,
combinations of Thiovir and zidovudine showed less cytotoxicity
than combinations of foscarnet and zidovudine, suggesting a safer
toxicity profile of the Thiovir and zidovudine combination.
Together, these results imply that Thiovir and zidovudine would be
compatible as part of an antiviral therapy. Copies of the poster
presentation will be available in the "Resources" section of the
Company's Web site at
http://www.adventrx.com/library/publications.htm. "The strong
antiviral activity demonstrated by combinations of Thiovir and
zidovudine is intriguing since it suggests that lower dosages of
each drug may be required when they are administered together to
achieve a level of viral inhibition," said Joan M. Robbins, Ph.D.,
ADVENTRX chief scientific officer and executive vice president.
"Furthermore, according to these preliminary results, combinations
of Thiovir and zidovudine do not increase the toxicity greater than
the sum of the toxicity from each of the drugs, which could have
important clinical implications from a drug tolerability
standpoint." ADVENTRX currently plans to file an investigational
new drug application (IND) with the US Food and Drug Administration
(FDA) in the first half of 2006 in order to conduct a Phase I/II
clinical trial using Thiovir to treat HIV/AIDS. In addition, the
Company is investigating Thiovir as a potential treatment for avian
influenza and is currently exploring international regulatory
strategies. The Company recently announced that Thiovir was active
against an H5N1 hybrid influenza strain. About Thiovir Thiovir is a
broad spectrum antiviral drug that has been shown in preclinical
tests to inhibit HIV, influenza A and herpes viruses. Thiovir is a
pyrophosphate analogue and reverse transcriptase inhibitor designed
for oral delivery as a component of highly active antiretroviral
therapy (HAART) for HIV/AIDS. Thiovir is a prodrug for foscarnet
that delivers both the active drug TPFA (thiophosphonoformate) and
the active metabolite PFA (foscarnet). About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last annual report on Form
10-K, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/
http://www.adventrx.com/library/publications.htm Company News
On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024